Gilead Sciences pharmaceutical company announced the expansion of the partnership with Pharmstandart in the sphere of the localization of medicines production for the treatment of socially important diseases in Russia, the company informed.
The companies signed the protocol of intentions aimed to implement Pharmstandart’s capacities for the production of medicines used for the treatment of C hepatitis and HIV.
During two years the above medicines are assumed to be launched in actual production.
In Aug. 2018 Gilead and Pharmstandart signed the first agreement on the localization of the secondary packaging of medicines at Pharmstandart-Leksredstva. The capacities of the latter permit to produce above 600mln packages of pharmaceuticals per year.
Gilead Sciences, Inc. is a research biopharmaceutical company that has been a leading innovator in the area of HIV control for over 30 years. Gilead operates in more than 35 countries around the world.
Pharmstandard is a leading Russian pharmaceutical company. The company’s production facilities include five factories located throughout Russia. The holders involve Augment Investments Limited, The Bank of New York International Nominees, Pharmstandart-Medicines.